Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
|Videos|November 8, 2021
Assessing the Link Between Senescence, Early Vascular Aging in Patients With Chronic Kidney Disease
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the link between senescence and early vascular aging in the context of chronic kidney disease.
Advertisement
Pharmacy Times interviewed Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer in the Department of Renal Medicine at Karolinska University Hospital in Karolinska Institutet, on his presentation at the American Society of Nephrology’s Kidney Week 2021 on vascular aging in chronic kidney disease (CKD).
During the interview, Stenvinkel discussed the link between senescence and early vascular aging in the context of CKD.
Advertisement
Related to this article
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
Preparing Pharmacists for Psychedelic Medicine
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5